Lexicon Pharmaceuticals Inc
NASDAQ:LXRX 11:10:03 AM EDT
Products
Lexicon Announces FDA Acceptance Of New Drug Application For Sotagliflozin To Treat Heart Failure
Published: 07/27/2022 12:29 GMT
Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure.
Lexicon Pharmaceuticals Inc - FDA Assigned a Standard Review for NDA Filing With a Prescription Drug User Fee Act (pdufa) Target Action Date in May 2023.
Lexicon Pharmaceuticals Inc - FDA Assigned a Standard Review for NDA Filing With a Prescription Drug User Fee Act (pdufa) Target Action Date in May 2023.